European cooperation could help to lower drug prices

摘要

The National Institute for Health and Clinical Excellence (NICE) acknowledges that thought should be given not only to a drug's effectiveness and quality adjusted life year (QALY) value but also to ways to influence the drug's cost.1 But in a free, efficient market, which the UK government is encouraging for healthcare purchasers and providers, it must be for individual pharmaceutical companies to decide whether it makes commercial sense to sell a drug to the NHSata price that allows it to meet the particular cost per QALY thresholds that NICE applies.